180 Life Sciences Corp represents the values of innovation, dedication, and patient-centric care. With a corporate philosophy focused on advancing solutions for inflammatory diseases and fibrosis, the company is committed to improving the lives of patients worldwide. Through extensive research and development, 180 Life Sciences Corp aims to develop groundbreaking therapies and medical interventions that address unmet medical needs. This dedication to scientific excellence and patient well-being drives the company's pursuit of novel treatments and advancements in the field of life sciences.

180 Life Sciences Corp is primarily present in the following countries and regions: United States of America (USA), Europe, and Canada.

180 Life Sciences Corp has achieved several significant milestones. Firstly, the company successfully completed its reverse merger with KBLM Acquisition Corp., enabling it to become a publicly traded entity. Additionally, 180 Life Sciences Corp has made notable progress in its research and development activities, particularly in the areas of inflammation and fibrosis. The company has collaborated with world-renowned academic institutions and has established strong partnerships with leading experts in the field. Furthermore, 180 Life Sciences Corp has expanded its pipeline of potential therapeutics, advancing novel drug candidates that have shown promising preclinical results. These achievements highlight the company's dedication to developing innovative solutions for various diseases and improving patient outcomes.

180 Life Sciences Corp is a pharmaceutical company focused on developing and commercializing innovative therapies for inflammatory diseases and fibrosis. Founded in [year], the company has a strong dedication to improving patient outcomes by targeting the underlying mechanisms of these conditions. With a robust pipeline of potential treatments, including clinical-stage drug candidates, 180 Life Sciences Corp strives to address unmet medical needs and make a positive impact in the field of healthcare. Through extensive research and collaborations, the company aims to revolutionize treatment options and enhance the quality of life for individuals suffering from inflammatory diseases and fibrosis.

Some of the main competitors of 180 Life Sciences Corp in the market include biopharmaceutical companies such as AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies also focus on developing and commercializing innovative therapies in the healthcare sector. However, 180 Life Sciences Corp distinguishes itself through its dedication to advancing novel treatments for inflammatory diseases and fibrosis conditions. With its unique research and development efforts, 180 Life Sciences Corp aims to stand out in the market and provide innovative solutions for patients worldwide.

180 Life Sciences Corp is primarily active in the pharmaceutical and biotechnology industries.

The business model of 180 Life Sciences Corp is focused on the development and commercialization of novel pharmaceutical products in the field of inflammatory diseases and fibrosis. The company aims to address unmet medical needs by identifying and advancing potential therapies through rigorous research and clinical trials. With a specialized focus on the development of targeted therapies, 180 Life Sciences Corp strives to improve patient outcomes and quality of life. By leveraging scientific expertise and strategic collaborations, the company aims to bring innovative and effective treatments to market, benefiting both patients and stakeholders in the healthcare industry.

180 Life Sciences P/E-luku on −0,01.

180 Life Sciences KUV on 0,09.

AlleAktien Laatuscore 180 Life Sciences on 3/10.

odotettu 180 Life Sciences liikevaihto on 8,47 milj. USD.

odotettu 180 Life Sciences voitto on −123,81 milj. USD.

180 Life Sciences Corp is a biopharmaceutical company based in the UK that develops innovative technologies for the treatment of inflammatory diseases. The company aims to significantly improve the quality of life for patients with chronic inflammatory conditions such as arthritis and fibromyalgia. The company follows a diversified business model that focuses on several areas. The main areas of the company include: - Research and development: 180 Life Sciences Corp conducts extensive research and development to develop innovative and effective drugs for the treatment of inflammatory diseases. The company has made significant progress in the areas of drug design and drug delivery systems. - Collaboration with strategic partners: The company forms targeted partnerships with leading pharmaceutical companies to enable commercialization of its products. 180 Life Sciences Corp collaborates closely with the University of Oxford and the Ferraresi Foundation to develop new technologies and conduct research activities. - Licensing: The company licenses its technologies and products to other companies. An example of this is the licensing of its technology for the production of transdermal patches to the pharmaceutical company Procter & Gamble. The products currently being developed by 180 Life Sciences Corp target the treatment of inflammatory diseases. The company's leading drug is a synthetic cannabidiol (CBD) product called SLS-002. This product is suitable for the treatment of inflammation and pain associated with arthritis and fibromyalgia. The company is also developing an inhalation device for the administration of cannabinoids. This device is intended to deliver the medication quickly and accurately to the lungs, increasing effectiveness and reducing necessary dosages. 180 Life Sciences Corp has also developed a technology for the production of transdermal patches. These patches are capable of delivering active ingredients directly through the skin, ensuring more effective absorption of the medication into the body. The company has entered into a licensing agreement with Procter & Gamble to utilize the transdermal patch technology. Overall, 180 Life Sciences Corp follows a promising business model based on a wide range of technologies and products for the treatment of inflammatory diseases. The company is working hard to further develop its technologies and establish new partnerships with other companies to bring its products to market.

180 Life Sciences maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea 180 Life Sciences:lle tai yhtiö ei maksa osinkoa.

180 Life Sciences:n ISIN on US68236V1044.

180 Life Sciences:n WKN on A2QJX5.

180 Life Sciences:n tunnus on ATNF.

Viimeisen 12 kuukauden aikana 180 Life Sciences maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana 180 Life Sciences maksanee ennusteiden mukaan 0 USD osingon.

180 Life Sciences:n tämänhetkinen osinkotuotto on .

180 Life Sciences maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

180 Life Sciences maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

180 Life Sciences kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän 180 Life Sciences osingon 18.9.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 18.9.2024.

Viimeisin osinko maksettiin 18.9.2024.

Vuonna 2023 180 Life Sciences maksoi 0 USD osinkoina.

180 Life Sciences:n osingot maksetaan USDssa.